Vimarsana
Biggest News Aggregation in the World

Page 2 - Why Target News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Why Target. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Why Target Today - Breaking & Trending Today

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (1) - Vimarsana News

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (1)

Published: October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United StatesRichard PhilipsonStanford HealthcaredateHong ZhangdateThierry ChristophedateJonathan BarrattRoisin ThomasdateNadia NawazRichard LafayettePennsylvania Convention CenterExhibit Hallsbd Pennsylvania Convention CenterUniversity Of LeicesterdateAmerican Society Of NephrologyAmerican SocietyKidney WeekPrimary IgaChief Medical OfficerPresentation DetailsNefigard PhaseGlomerular DiseasesPresentation VenueBreaking Poster Presentation DetailsLate Breaking PostersExhibit Hallsb DGenetic Diseases
Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) Septembe - Vimarsana News

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) Septembe

Published: September 19, 2023

STOCKHOLM, Sept. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:...

Source: europapress.es
Related Topics:
Hong ZhangRichard LafayetteHeathern ReichAndrew StoneVladimir TesarNadia NawazRoisin ThomasBradh RovinJens KristensenKaren MolyneuxJonathan BarrattAlexander PaliegeUniversity Of LeicesterInternational Symposium On Iga Nephropathy IigExchange CommissionNasdaq StockholmNeflgard PhaseInternational SymposiumIga NephropathyPrimary IgaPresentation DetailsNefigard PartNefigard PhaseNecmi ErenVicky Cotton
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO - Vimarsana News

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO

Published: June 21, 2023

Calliditas Therapeutics AB today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration seeking full approval of TARPEYO® delayed release... | June 21, 2023

Source: marketscreener.com
Related Topics:
Exchange CommissionDrug AdministrationCalliditas TherapeuticsNasdaq StockholmNew Drug ApplicationFull PrescribingIga NephropathyPrimary ImmunoglobulinNasdaq Global Select MarketPrivate Securities Litigation Reform ActWhy TargetTreat IgaKidney Int RepNationwide Population Based Cohort
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® - Vimarsana News

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Published: June 21, 2023

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a supplemental New Drug...

Source: prnewswire.com
Related Topics:
Exchange CommissionDrug AdministrationNasdaq StockholmNew Drug ApplicationFull PrescribingIga NephropathyPrimary ImmunoglobulinNasdaq Global Select MarketPrivate Securities Litigation Reform ActCalliditas TherapeuticsWhy TargetTreat IgaKidney Int RepNationwide Population Based Cohort
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval - Vimarsana News

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval

Published: June 21, 2023

STOCKHOLM, June 21, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
Drug AdministrationExchange CommissionNasdaq StockholmNew Drug ApplicationFull PrescribingIga NephropathyPrimary ImmunoglobulinNasdaq Global Select MarketPrivate Securities Litigation Reform ActCalliditas TherapeuticsWhy TargetTreat IgaKidney Int RepNationwide Population Based Cohort